Abstract: Present invention is a system of blood glucose monitoring and intensive insulin therapy in a ICU for strict maintenance of normoglycemia which reduces intensive care and hospital mortality and morbidity of critically ill adult patients. The findings of present study also reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome benefits have been established. The invention provides a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity). This automated insulin monitoring systems significantly reduces the workload and human resource management problems for intensive insulin therapy in patients in the ICU.

Abstract: A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.

Abstract: Laser interferometers and high-quality linear encoders both are competitive linear measurement systems used in high-precision machines. Plane laser interferometry allows measuring to a target that moves perpendicular to the measurement direction and to set up the laser beam in line with the functional point. In this way, a stacking of measurement systems can be avoided and a measurement configuration complying with the Abbe principle can be configured. On the other hand, laser interferometry is known to be sensitive to environmental changes. High-quality linear scales are used as an alternative. A disadvantage of linear scales is that the target is only allowed to move along the measurement axis. For targets translating in more than one direction with a range over several millimeters, this leads to a simple stacking of several linear scales together with the supporting slides. This indirect way of measuring introduces errors and partially destroys the accuracy provided by modern linear scales.

Abstract: The destruction of chlorinated hydrocarbons, such as carbon tetrachloride, over lanthanide-based solid catalysts in the presence of steam has been investigated between 200 and 350° C. Ln2O3/AL2O3 (e.g. Ln=La, Nd, Ce and Pr) show a very high catalytic hydrolysis activity. The destruction capacity gradually increases with increasing temperature and reaches a maximum value of 42.3·106 ppm.h?1 at 350° C. for a 10 wt % Ln2O3/AL2O3 catalyst This destruction capacity could be maintained for a least 48 hours. The catalyst activity is also function of the type of lanthanide oxide; i.e., La?Nd>Ce?Pr. The process is based on a delicate equilibrium between destructive adsorption of CCI4 onto the lanthanide oxide and the dechlorination of the formed lanthanide chloride with steam. Steam being responsible for the in situ regeneration of the catalytic active phase.

Abstract: The present invention provides novel inhibitors of angiogenesis. The invention relates to PF4var1 and fragments and modifications thereof with anti-angiogenic activity. Therefore, the present invention relates to the use of said proteins and peptides as a medicine, more in particular for the treatment or prevention of angiogenesis or for the manufacture of a medicament for the prevention or treatment of angiogenic diseases. The invention also provides pharmaceutical compositions comprising said proteins and peptides and method of preventing or treating angiogenic disorders.

Abstract: The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are useful for the treatment of subjects suffering from viral infections.

Abstract: The essence of the invention is the use of supercooled superconductors for generation of high-frequency electric oscillations. The superconductor is supercooled, i.e. in the normal phase at a temperature lower than the critical transition temperature for superconductivity, under an applied electric energy source. In such non equilibrium conditions the superconductor can have negative differential conductivity which can be used as an active medium in generators of electric (current and voltage) oscillations. Such generators can be used in the superconducing electronics. Oscillation can be modulated by the change of bias voltage, electrostatic doping by a gate electrode, or by light. When small amplitude oscillations are stabilized near to the critical temperature the generator can be used as a bolometer. The supercooled superconductors can be used also as transistors and frequency mixers. The negative differential conductivity of superconductor is created by the excess conductivity of fluctuation Cooper pairs.

Abstract: The present invention relates to the use of modified nucleotides and single or double stranded oligonucleotides having at least one of said modified nucleotides for performing RNA interference. The modified nucleotides are selected from 6-membered ring containing nucleotides such as hexitol, altritol, O-substituted or O-alkylated altritol, cyclohexenyl, ribo-cyclohexenyl and O-substituted or O-alkylated ribo-cyclohexenyl nucleotides. The present invention also relates to novel modified nucleosides or nucleotides and to the use of the novel modified nucleosides and nucleotides in single or double stranded oligonucleotides for RNA interference, antisense therapy or other applications.

Abstract: A half closed thermoplastic folded honeycomb structure is described which is produced from a continuous web of material by plastic deformation perpendicular to the plane of the material to thereby form half-hexagonal cell walls and small connecting areas. By folding in the direction of conveyance the cell walls meet to thereby form the honeycomb structure.

Abstract: The invention provides a process of making porous structures or materials, including the colloidal processing (e.g. slip casting, pressure casting, tape casting or electrophoretic deposition) of solid particle emulsions to form a green body that can be directly sintered without a de-binding step.

Abstract: A system and method for pre-operatively obtaining a prediction of a post-operative image of at least part of a body is disclosed. A 3D pre-operative description is determined of at least part of a body, and a pre-operative 2D photograph is acquired of the at least part of the body from any viewing position. The 3D pre-operative description is matched with the pre-operative 2D photograph, and a deformation field is determined for deforming the 3D pre-operative description. A predicted post-operative image of a 3D post-operative description of the at least part of the body is derived by means of the deformation field and the pre-operative 2D photograph.

Abstract: Method and apparatus for reducing the average size of metallic compound particles or agglomerates suspended in a fluid by flowing one or more times said fluid having metallic compound particles or agglomerates suspended therein through one or more magnetic fields to reduce the average size of a substantial portion of the metallic compound particles or agglomerates by at least 25%.

Abstract: The present invention is concerned with a method and composition for use in the medical art. It relates to the prevention and/or minimization of Spondyloarthropathies (SpA) and/or SpA enthesitis. SpA are an important group of chronic inflammatory disorders, affecting both the axial and peripheral skeleton. A particular method and composition optionally including a suitable dispensing device for such compositions can be used for ameliorating or preventing SpA. The invention applies to human and veterinary applications. To date, no single therapeutic approach has proven universally effective in preventing SpA or ameliorating SpA. Therefore, there is a need for compositions and methods which may be used safely and effectively to prevent SpA in a variety of different contexts.

Abstract: The present invention relates to a nutritional additive comprising arabinoxylans, which beneficially modulates the human intestinal flora. Furthermore, several food and beverage products comprising the additive are provided as well as methods to prepare the said additive.

Abstract: This invention relates to antagonists of placental growth factor and signalling thereof, pharmaceutical compositions containing such antagonists and the use of such antagonists to prevent bone loss or bone mass and to enhance bone healing including the treatment of conditions which present with low bone mass and/or bone defects in vertebrates, and particularly mammals, including humans.

Abstract: The present invention relates to genes encoding proteins involved in regulated secretion which are linked with the occurrence of or the susceptibility to a neural system disorder. The invention thus also relates to methods of identifying patients which have been diagnosed with a neural system disorder as susceptible to the treatment with modulators of regulated secretion.

Abstract: The invention relates to the field of phagocytosis and more particularly to the field of neurons and neuron diseases. In particular the invention relates to the use of molecules capable of modulating the phagocytosis in neurons, more particularly to molecules modulating the activity of telencephalin.

Abstract: A ligand derived from, e.g. a Fab fragment of, a monoclonal antibody obtainable from the cell line deposited with the Belgian Coordinated Collections of Micro-organisms under accession number LMBP 5108CB binds to the human platelet glycoprotein GPib and prevents the binding of von Willebrand factor to said GPIb without inducing thrombocytopenia. The said ligand is useful, in admixture with a pharmaceutically acceptable carrier, in a pharmaceutical composition, optionally further comprising a thrombolytic agent, for preventing and/or treating haemostasis disorders.

Abstract: Novel vitamin D analogues are useful for making pharmaceutical compositions for the prevention or treatment of bone disorders such as osteoporosis

Abstract: The present invention relates to the use of matrices in cell recruitment and the to modified matrices comprising homing factors for in vivo recellularisation of implantable medical devices such as cardiac valves and vascular grafts.